The current financial score of Tempest Therapeutics Inc is 6.98. Its financial status is robust, and its operating efficiency is low.
The current valuation score of Tempest Therapeutics Inc is 9.29. Its current P/E ratio is 0.02, which is 177.35% below the recent high of 0.06 and 247139.32% above the recent low of -57.81.
The current earnings forecast score of Tempest Therapeutics Inc is 8.00. The average price target is 11.00, with a high of 11.00 and a low of 11.00.
The current price momentum score of Tempest Therapeutics Inc is 5.38. Currently, the stock price is trading between the resistance level at 1.02 and the support level at 0.62, making it suitable for range-bound swing trading.
The current institutional shareholding score of Tempest Therapeutics Inc is 3.00. The latest institutional shareholding proportion is 31.43%, representing a quarter-over-quarter increase of 278.70%.
The current risk assessment score of Tempest Therapeutics Inc is 2.61. The company's beta value is -1.78. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.